Is resveratrol the magic bullet for pulmonary hypertension?

Hypertension

Volumn 54, Issue 3, 2009, Pages 473-474

  Chicoine, Louis G ^a   Stewart Jr , James A ^a   Lucchesi, Pamela A ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCROTALINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN C JUN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; STILBENE DERIVATIVE; VASODILATOR AGENT;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOLOGICAL MODEL; BLOOD PRESSURE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PULMONARY ARTERY; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HYPERTENSION, PULMONARY; MODELS, BIOLOGICAL; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PULMONARY ARTERY; RATS; STILBENES; TUMOR NECROSIS FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 70349260427     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135251     Document Type: Note

References (11)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43: 5S-12S.
2. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther. 2007;29: 2134-2153. (Pubitemid 350138566)
3. Csiszar S, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54:668-675.
4. Weir EK, Olschewski A. Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc Res. 2006;71:630-641.
5. 2+ entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001;280:H746-H755.
6. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev. 2004;22:169-188.
7. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, Ito K, Russell RE, Barnes PJ. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol. 2004;287:L774-L783.
8. Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY, Kim K. Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol. 2008;51:71-77.
9. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaBindependent mechanism. FASEB J. 2005;19:840-841.
10. Poussier B, Cordova AC, Becquemin JP, Sumpio BE. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg. 2005;42:1190-1197.
11. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol. 2007;50:83-93.